Doxorubicin is an anthracycline antineoplastic agent, used in treatment protocols for various cancers.

**General description**

Doxorubicin is an anthracycline antineoplastic agent, used in treatment protocols for various cancers.

**INN**

Doxorubicin

**ATC codes**

L01DB01 L01AA01

**Medicine type**

Chemical agent

**EML status history**

- First added in 1977 (TRS 615) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Added in 2011 (TRS 965) for Lymphoid leukaemia, not elsewhere classified
- Added in 2011 (TRS 965) for Burkitt lymphoma including Burkitt leukaemia
- Added in 2015 (TRS 994) for Follicular lymphoma
- Added in 2015 (TRS 994) for Malignant neoplasms of breast
- Added in 2015 (TRS 994) for Hodgkin lymphoma
- Added in 2015 (TRS 994) for Kaposi sarcoma of unspecified primary site
- Added in 2015 (TRS 994) for Diffuse large B-cell lymphomas
- Added in 2015 (TRS 994) for Malignant neoplasms of kidney, except renal pelvis
- Added in 2015 (TRS 994) for Ewing sarcoma of bone and articular cartilage of unspecified sites
- Added in 2015 (TRS 994) for Osteosarcoma of bone and articular cartilage of unspecified sites
- Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Added in 2015 (TRS 994) for Other specified malignant neoplasms of breast
- Added in 2019 (TRS 1021) for Plasma cell myeloma
- Application rejected in 2021 (TRS 1035) for Rhabdomyosarcoma primary site
- Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive
- Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative

**Recommendations**

- [Wikipedia](https://en.wikipedia.org/wiki/Doxorubicin)
- [DrugBank](https://www.drugbank.ca/drugs/DB00092)
Section: Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

- Diffuse large B-cell lymphomas
- Malignant neoplasms of breast
- Hodgkin lymphoma
- Kaposi sarcoma of unspecified primary site
- Follicular lymphoma
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Osteosarcoma of bone and articular cartilage of unspecified sites
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Lymphoid leukaemia, not elsewhere classified
- Malignant neoplasms of kidney, except renal pelvis
- Burkitt lymphoma including Burkitt leukaemia
- Other specified malignant neoplasms of breast
- Plasma cell myeloma
- Rhabdomyosarcoma primary site
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative